The Cancer Biology and Biotechnology Research Program at the University of New Mexico Cancer Center is a highly interactive transdisciplinary program with 24 Program Members from 6 Departments in the UNM School of Medicine (Biochemistry and Molecular Biology, Cell Biology and Physiology, Medicine, Molecular Genefics and Microbiology, Neurology, and Pathology), the UNM College of Pharmacy, 3 Departments on the UNM Main Campus (Biology, Chemical and Nuclear Engineering, and Physics and Astronomy), New Mexico State University (Chemistry), and Sandia and Los Alamos Nafional Laboratories. The Program has two scientific themes;the first: Chromosome Dynamics and Macromolecular Interactions has the goals of (1) discovering the fundamental mechanisms of tumorigenesis through studies of epigenefic, transcripfional, cell growth control, and DNA damage repair pathways in cancer cells and model organisms;and (2) exploiting studies of viral protein-nucleic acid interacfions for translafion into new dlagnosfic or therapeufic platforms. The second program theme: Biotechnology and Target Screening has the overall goal of discovering and validating novel targets and small molecules from these fundamental regulatory pathways for cancer diagnosis, screening, prevention, and therapy. To achieve the goals of this second theme, program members develop and utilize (1) high-throughput small molecule screening, high performance compufing, cheminformafics, and animal modeling;(2) novel isotopes and imaging;and (3) micro- and nanotechnology to discover, screen, and model new cancer targets. Since the prior NCI CCSG review in 2005, the Program's funding, intraprogrammafic, and inter-programmafic interacfions have all increased dramafically. Program members direct one of only 9 nafional, mulfi-invesfigator NIH Roadmap-funded Center Grants for target screening and chemical biology: The UNM Center for Molecular Discovery (U54MH084690) which is collaborating with each UNM Cancer Center Research Program and several other NCI Cancer Centers to screen and characterize over 30 novel cancer targets. Program members also recenfiy received nofice of the funding of two highly compefifive NCI ARRA Challenge Grants {RC2CA148982;RC1EB/CA010617). As of September 2009, Program Members at the UNM Cancer Center and its consortium institufions held $9,538,635 in total annual direct funding (represenfing an 80% increase in funding since 2005) of which $8,365,143 was peer-reviewed ($1,537,027 from NCI and $6,828,116 from NIH, NSF, DOD, and DOE). Program members at New Mexico State University held an additional $2,965,296 in annual peer-reviewed funding. In 2008, program members published a total of 53 cancer-relevant publicafions, of which 27% were intra-programmafic and 48% were inter-programmatic.

Public Health Relevance

Cancer is a multifactorial disease that requires transdisciplinary approaches to understand its etiology and translate these discoveries to more effective diagnostics and therapeutics. The goals of The Cancer Biology and Biotechnology Program are to study the most fundamental cellular pathways that are perturbed in human cancers and that promote cancer efiology and progression and to develop and use the most innovative science and technology to discover and characterize new cellular targets that can be used to diagnosis, screen, prevent, and treat human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA118100-10
Application #
8723071
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
10
Fiscal Year
2014
Total Cost
$29,345
Indirect Cost
Name
University of New Mexico Health Sciences Center
Department
Type
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Castleman, Moriah J; Pokhrel, Srijana; Triplett, Kathleen D et al. (2018) Innate Sex Bias of Staphylococcus aureus Skin Infection Is Driven by ?-Hemolysin. J Immunol 200:657-668
Barton, Matthias; Filardo, Edward J; Lolait, Stephen J et al. (2018) Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. J Steroid Biochem Mol Biol 176:4-15
Prossnitz, Eric R (2018) GPER modulators: Opportunity Nox on the heels of a class Akt. J Steroid Biochem Mol Biol 176:73-81
Perez, Dominique R; Nickl, Christian K; Waller, Anna et al. (2018) High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. SLAS Discov 23:732-741
Pallikkuth, Sandeep; Martin, Cheyenne; Farzam, Farzin et al. (2018) Sequential super-resolution imaging using DNA strand displacement. PLoS One 13:e0203291
Leng, Shuguang; Picchi, Maria A; Kang, Huining et al. (2018) Dietary Nutrient Intake, Ethnicity, and Epigenetic Silencing of Lung Cancer Genes Detected in Sputum in New Mexican Smokers. Cancer Prev Res (Phila) 11:93-102
Peretti, Amanda S; Dominguez, Dayna; Grimes, Martha M et al. (2018) The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice. Am J Pathol 188:515-524
Brandsma, Arianne M; Schwartz, Samantha L; Wester, Michael J et al. (2018) Mechanisms of inside-out signaling of the high-affinity IgG receptor Fc?RI. Sci Signal 11:
Zheng, Handong; Wu, Dandan; Wu, Xiang et al. (2018) Leptin Promotes Allergic Airway Inflammation through Targeting the Unfolded Protein Response Pathway. Sci Rep 8:8905
Ray, Anita L; Berggren, Kiersten L; Restrepo Cruz, Sebastian et al. (2018) Inhibition of MK2 suppresses IL-1?, IL-6, and TNF-?-dependent colorectal cancer growth. Int J Cancer 142:1702-1711

Showing the most recent 10 out of 344 publications